DC vaccine

BIOLOGICAL17 trials

Sponsors

Mackay Memorial Hospital, Dartmouth-Hitchcock Medical Center, Inge Marie Svane, Pawel Kalinski, Zwi Berneman

Conditions

Acute Myeloid LeukemiaBreast CancerCarcinoma, HepatocellularCarcinoma, Non-Small-Cell LungColorectal CancerColorectal CarcinomaColorectal NeoplasmsColorectal Tumors

Phase 1

Transfected Dendritic Cell Based Therapy for Patients With Breast Cancer or Malignant Melanoma

CompletedNCT00978913

Inge Marie SvaneBreast Cancer, Malignant Melanoma

Start: 2009-09-30End: 2014-05-31Updated: 2015-08-19

Safety of Labeled Dendritic Cell (DC) Vaccines and Feasibility of Tracking by Magnetic Resonance Imaging (MRI)

CompletedNCT01671592

Pawel KalinskiColorectal Cancer, Colorectal Carcinoma, Colorectal Neoplasms +2

Start: 2013-01-31End: 2014-04-30Updated: 2017-09-26

αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies

CompletedNCT02151448

David BartlettMalignant Neoplasm of Pancreas Metastatic to Peritoneal Surface, Malignant Peritoneal Mesothelioma, Peritoneal Carcinomatosis

Start: 2014-07-31End: 2019-02-18Updated: 2020-07-20

DC Vaccination in CML

TerminatedNCT02543749

Charite University, Berlin, GermanyMyeloid Leukemia, Chronic

Start: 2014-07-31End: 2022-07-31Updated: 2023-02-09

Personalized DC Vaccine for Lung Cancer

Sichuan UniversityCarcinoma, Non-Small-Cell Lung

Start: 2016-11-30End: 2020-06-01Target: 20Updated: 2018-05-31

DC Vaccine in Colorectal Cancer

TerminatedNCT03730948

University of PennsylvaniaColorectal Cancer

Start: 2019-03-12End: 2022-12-01Updated: 2024-05-24

Safety and Efficacy Study for MG-7-DC Vaccine in Gastric Cancer Treatment

The Second Hospital of Shandong UniversityGastric Cancer

Start: 2020-09-30End: 2022-06-30Target: 45Updated: 2020-09-28

Hypomemylating Agents Combination With eDC Therapy for Elderly Patients With Myelodysplastic Syndrome

RecruitingNCT04999943

Affiliated Hospital to Academy of Military Medical SciencesDendritic Cell, Hypomethylating Agents, Immunotherapy +1

Start: 2021-07-01End: 2026-07-01Target: 40Updated: 2021-08-11

Phase 2

Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients

TerminatedNCT00913913

Dartmouth-Hitchcock Medical CenterMetastatic Renal Cell Carcinoma

Start: 2009-02-28End: 2013-01-31Updated: 2015-12-01

Dendritic Cell Based Therapy for Breast Cancer Patients

WithdrawnNCT00935558

Inge Marie SvaneBreast Cancer

Start: 2009-07-31Updated: 2012-05-31

Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission

Active, not recruitingNCT01686334

Zwi BernemanAcute Myeloid Leukemia

Start: 2012-10-31End: 2027-12-31Target: 130Updated: 2024-03-12

Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma

CompletedNCT01876212

Walter J. StorkusMetastatic Melanoma

Start: 2014-05-16End: 2019-07-31Updated: 2019-08-22

A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence

CompletedNCT02334735

Nina BhardwajMelanoma

Start: 2015-07-01End: 2020-07-15Updated: 2022-09-15

Unknown Phase

Cytotoxicity Induced by Tumor Lysate Pulsed Dendritic Cells Against Autologous Hepatocellular Carcinoma Cells

Mackay Memorial HospitalCarcinoma, Hepatocellular

Start: 2005-06-30End: 2006-06-30Target: 10Updated: 2006-05-18

Clinical Study of DC-AML Cells in the Treatment of Acute Myeloid Leukemia

RecruitingNCT05000801

Affiliated Hospital to Academy of Military Medical SciencesAcute Myeloid Leukemia

Start: 2021-07-01End: 2026-07-01Target: 20Updated: 2021-08-20

MMR/MSI Phenotypes in Prediction of Tumor Vaccine Benefit for Gliomas

RecruitingNCT06043232

Huashan HospitalGlioma

Start: 2023-09-30End: 2026-03-31Target: 360Updated: 2023-09-21

A Clinical Study of Personalized Self-DC Vaccine Targeting Neoantigen in Treatment of Advanced Solid Tumor

RecruitingNCT06682117

Fudan UniversityNeoantigen, Solid Tumor Cancer, Treatment +1

Start: 2024-11-15End: 2026-12-30Target: 9Updated: 2026-04-02

Related Papers

A randomized phase II trial of neoadjuvant chemokine modulation in patients with localized prostate cancer undergoing radical prostatectomy.

Journal of Clinical Oncology2023-02-20

Abstract CT108: Immunogenicity of Poly-ICLC matured dendritic cells as an adjuvant for NY-ESO-1 and Melan-A-MART-1 peptide vaccination compared to Montanide® ISA-51 VG, in study subjects with melanoma in complete clinical remission but at high risk of disease recurrence

Cancer Research2022-06-152 citations

Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma

Journal for ImmunoTherapy of Cancer2021-11-0150 citations

Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer.

2021-01-20194 citations

A phase II open labeled, randomized study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared to Montanide, in melanoma patients in complete clinical remission.

Journal of Clinical Oncology2019-05-204 citations

Neoantigen-based personalized DC vaccine for lung cancer: An update of translational study.

Journal of Clinical Oncology2019-05-202 citations

Neoantigen-based personalized, immune cell therapy for patients with advanced NSCLC: A pilot study.

Journal of Clinical Oncology2018-05-20

Dasatinib promotes an expanded and therapeutically-superior T cell repertoire in response to vaccination against melanoma (VAC12P.1014)

The Journal of Immunology2014-05-01

Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients.

2012-08-21143 citations